Background Patients diagnosed with high risk localized prostate cancer have variable
outcomes following surgery. Trials of intense neoadjuvant androgen deprivation therapy (NADT) …

PURPOSE Despite decreased screening-based detection of clinically insignificant tumors,
most diagnosed prostate cancers are still indolent, indicating a need for better strategies for …

Localized prostate cancers are genetically variable and frequently multifocal, comprising
spatially distinct regions with multiple independently-evolving clones. To date there is no …

Purpose: For high-risk prostate cancer, standard treatment options include radical
prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive …

Localized prostate cancer develops very slowly in most men, with the androgen receptor (AR)
and MYC transcription factors amongst the most well-characterized drivers of prostate …

Patients diagnosed with localized high-risk prostate cancer have uncertain outcomes, and
the introduction of neoadjuvant intensive hormonal therapies seeks to treat occult …

Purpose: Neoadjuvant intense androgen deprivation therapy (iADT) can exert a wide range
of histological responses, which in turn are reflected in the final prostatectomy specimen. …

Human cancer tissues are known to release their own DNA into body fluids such as plasma.
These DNA molecules derived from tumors, collectively known as circulating tumor DNA (…

Background: Molecular characterization of mCRPC has revealed disruption of DNA damage
repair genes that may improve sensitivity to PARP inhibitors such as olaparib (O), which in …

Background: Intense neoadjuvant androgen deprivation therapy (inADT) reduces prostate
cancer recurrence in approximately 40% of patients with intermediate/high risk prostate cancer…